Visible results can be seen as early as week 1*1,2
For illustrative purposes only. Images are of a representative individual psoriasis patient from the PSO-FAST study (DoF LEO90100 – 003)1
*8.5% (n=27/323) of patients using Enstilar® achieved treatment success by week 1 vs. 1.0% (n=1/103) of patients using foam vehicle (not significant).
PSO-FAST was a Phase III, multicentre (US), double-blind, vehicle-controlled, 4-week study. Treatment success was defined as clear or almost clear skin (for patients with ≥moderate disease at baseline) or clear skin (for patients with mild disease at baseline), according to PGA. The primary endpoint was the proportion of patients at week 4 who achieved treatment success: 53.3% (n=172/323) of patients using Enstilar® vs. 4.8% (n=5/103) of patients using foam vehicle (OR, 30.3; 95% CI, 9.7 to 94.3; P<0.001).2 CI, confidence interval; OR, odds ratio; PGA, physician’s global assessment.
Leonardi C et al. J Drugs Dermatol 2015; 14(12):1468–1477.
UK/IE MAT-04296 V4
Date of preparation: September 2018
Cookies on this site